UPClytics
View all cases

UPC CoA 405/2024

Jul 11, 2024·EP3167888 Unitary patent · TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Case details
Status
Case Closed
Action
Appeal
Category
Main appeal
Parties
Claimants
Representatives
Respondents
Representatives
Division
Court of Appeal
Technology
  • Chemistry
    Biotechnology · Pharmaceuticals
Language
English
First decided
Jul 30, 2024
Last decision
Jun 19, 2025
EPO Opposition
How this compares
How long the court takes to reach a first decision.
Median days to first decision
All UPC124
Judge Rian KaldenLocked
Judge Patricia RombachLocked
Judge Ingeborg SimonssonLocked

At the UPC: AstraZeneca Group (13 cases)·Amgen Group (19 cases)

This dispute contains 2 other proceedings

UPC APP 43687/2024·UPC CFI 124/2024

6 other defendants litigating the same or a related patent

UPC CoA 744/2025·UPC CFI 674/2025·UPC CFI 51/2025·UPC CFI 642/2024·UPC CoA 402/2024 and 1 more

Start a free trial to see how each one ended.

More cases: Court of Appeal·2024

Decisions
  • 2025-06-19

    Summary: The Court of Appeal set out general principles for rehearing applications under Art. 81(1)(b) UPCA, establishing that only fundamental procedural defects that would have led to a different outcome can justify rehearing, in proceedings where Alexion sought to reopen a dismissed provisional measures appeal against Amgen concerning EP 3 167 888.

    Show the legal issues (3)
    • Rehearing application (Art. 81(1) UPCA, R. 245 RoP)
    • Fundamental procedural defect
    • Standard for reopening final decisions
  • 2024-12-20
    Appeal RoP220.1Public

    Summary: The Court of Appeal dismissed Alexion's appeal against the first-instance refusal of provisional measures, upholding the finding that the patent claim could not be corrected by interpretation to remove alleged errors, and confirming that claim 2 of EP 3 167 888 was more likely than not insufficiently disclosed (Article 83 EPC). The provisional measures application was therefore denied.

    Show the legal issues (5)
    • Claim interpretation — correction of errors
    • Insufficiency of disclosure (Article 83 EPC)
    • Provisional measures
    • Claim interpretation from perspective of skilled person
    • Patent prosecution history (TBA proceedings)
  • 2024-08-08

    Summary: The Court of Appeal ruled that service of written pleadings must be effected through the Court's electronic CMS and that prior communication via Germany's beA (besonderes elektronisches Anwaltspostfach) does not constitute effective service under R.278.1 RoP.

    Show the legal issues (4)
    • Service of documents
    • R.278.1 RoP
    • Electronic CMS service
    • beA (besonderes elektronisches Anwaltspostfach)
  • 2024-07-30

    Summary: The Court of Appeal rejected Alexion Pharmaceuticals' request to expedite the appeal against the Hamburg Local Division's refusal to grant provisional measures against Amgen, holding that the circumstances were not sufficiently urgent to justify shortening the time period for the respondents to lodge their statement of response.

    Show the legal issues (5)
    • Expedition of appeal
    • R.9.3(b) RoP
    • Shortening of deadlines
    • Provisional measures appeal
    • R.225(e) RoP
Document titleDatePublic
Cover sheet2025-11-25Not public
Other document Appellant2025-11-25Not public
Receipt2025-11-25Not public
20250721_Confidentiality_Request_re_Application_cost_decision_rehearing2025-07-21Not public
20250721_Confidentiality_Request_re_Application_cost_decision_rehearing2025-07-21Not public
20250721_Application_cost_decision_rehearing_Confidential2025-07-21Not public
Headnote-and-Keywords2025-06-19Not public
Outcome of the Order2025-06-19Not public
Decision2025-06-19Public
Exhibit_BP_33_Amgen_en2025-05-12Not public